Biocon, Mylan launch cancer drug in Australia

Fulphila, co-developed by Biocon Biologics and Mylan, was the first biosimilar pegfilgrastim to be approved in the US and was launched in July 2018, thus expanding access for patients in need of an affordable alternative.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3emCDvR
via IFTTT